Medical Developments International Limited · ASX:MVP
Medical Developments International — Non-Deal Roadshow (May 2016)
28 slides from Medical Developments International's roadshow presentation, May 30, 2016
Slide 1: Medical Developments International USA Road Show
For personal use only Medical Developments International USA Road Show
Slide 2: Vision
Vision For personal use only Medical Developments International (MDI) is a leading Emergency Medicine Company. Our aim is to: 1. Dominate the analgesic trauma and minor surgical procedures internationally. 2. Dominate the Medical Devices market internationally. 3. Provide unique and innovative produ
Slide 3: Vision
Vision For personal use only MDI is delivering two world class “company making” business opportunities. The risk profile of these opportunities is relatively low and well understood. Penthrox: Penthrox has the potential to be the market leader in analgesic markets in the USA, Europe and elsewhere. P
Slide 4: A world class opportunity
Penthrox A world class opportunity For personal use only Potential global sales $2 billion+ Peak sales in UK estimated to be $72 million per annum* Peak sales in Europe Peak sales in Canada could be estimated to be $250 million $50 million per annum* per annum* Peak sales in Asia Peak sales in USA c
Slide 5: A world class opportunity in the USA
Penthrox A world class opportunity in the USA For personal use only 136 million admissions to the 32 million possible Penthrox ER each year in the USA* cases pa* Additional Future Indications Significant non narcotic bias for include: treatment of pain in the ER and • Minor surgical procedures elsew
Slide 6: Why Penthrox in the USA?
Penthrox Why Penthrox in the USA? For personal use only Non-narcotic trauma relief, Penthrox can materially improve the non-addictive, safe.1 throughput of patients7,8 in the ER because it enables better time to analgesia and less Not a restricted medicine medical care and observation compared to na
Slide 7: A world class opportunity: Penthrox
Penthrox A world class opportunity For personal use only Penthrox® • Market Leader for trauma pain • Opiate sparing, fast acting inhalational analgesic 1 • 85% of patients reach clinical analgesia within 10 breaths • Is a solution to a significant unmet clinical need • Demonstrated safety and effica
Slide 8: A world class opportunity: Penthrox
Penthrox A world class opportunity For personal use only Penthrox® • Sold in 15 countries around the world including Australia, UK, Europe, South Africa, Singapore with France and Belgium in the coming months. • Major distribution deals signed in Europe and elsewhere in 2015. • $12 million in upfron
Slide 9: Clinical application
Penthrox Clinical application For personal use only Painful procedures Painful procedures Cosmetic Dentistry Surgery • Cutaneous excisions • Burn injuries • Liquid nitrogen • Breaks, Military Consulting removals of skin- fractures and Rooms cancers, warts, etc. dislocations • Invasive • Abdomen pain
Slide 10: Non-narcotic and clinically proven efficacy
Penthrox Non- narcotic and clinically proven efficacy For personal use only VAS scores compared, IV morphine vs IN fentanyl vs Penthrox Summary of mean VAS Pain Scores The criteria for the cross study comparison were a similar study design and endpoint as the Penthrox® Time 0 5 minutes 10 minutes 15
Slide 11: Benefits to medical professionals
Penthrox Benefits to medical professionals For personal use only Rapid onset of Minimal waiting time before a painful procedure can be performed action (3 minutes) and rapid pain relief when a patient is treated for burns, trauma, etc. Inhaled self- Medical professionals can perform a procedure/atte
Slide 12: Benefits over Nitrous Oxide
Penthrox Benefits over Nitrous Oxide For personal use only The benefits of using Penthrox® over Nitrous Oxide include: • Penthrox does not effect vital signs; no clinical depression of respiration or circulation. • Penthrox is self-administered and easy to use. • Penthrox is compact and can be used
Slide 13: Benefits over Morphine
Penthrox Benefits over Morphine For personal use only The benefits of using Penthrox® over Morphine are the same as detailed for Nitrous. In addition there more specific benefits Penthrox has over Morphine include: • Penthrox does not effect vital signs; no clinical depression of respiration or circ
Slide 14: Manufacturing
Penthrox Manufacturing For personal use only MDI has invested millions of dollars developing new manufacturing techniques and methods and creating valuable intellectual property. MDI has: 1. World leading intellectual property. 2. Global production capacity. 3. Lowest cost to manufacture. 4. Signifi
Slide 15: Intellectual Property
Penthrox Intellectual Property For personal use only MDI is protecting its future by generating intellectual property from its manufacturing technology and delivery devices. In the last 12 months MDI has filed and is managing the following patents and trademarks: • 4 Penthrox Inhaler patents • 1 CSI
Slide 16: Future
Penthrox Future For personal use only We have achieved and should continue to achieve a number of significant regulatory approvals in Europe and around the world during 2015, 2016 and 2017. Our Regulatory Dossier is now proven to be world class and capable of being accepted by Regulatory Authorities
Slide 17: Future
Penthrox Future For personal use only In addition to the global trauma market, MDI has plans to develop applications for its products in the following markets: • Minor Surgical Procedure • Military • Break Through Pain (cancer and post operative) • Home Use trauma • World Aid (no needles, opioid's o
Slide 18: Future: Conclusion
Penthrox Future : Conclusion For personal use only MDI has: • product already being sold in markets around the world; • spent more than $10 million and successfully completed a range of Pivotal Phase III trials used to develop a Regulatory Dossier capable of getting Penthrox approved for sale anywhe
Slide 19: MDI Medical Respiratory division
MDI Medical Respiratory division For personal use only MDI has a long history of investing R&D resources to design and improve respiratory devices used to deliver Asthma and COPD medication. In 2011 MDI launched a new range of products using MDI’s Cross Valve TechnologyTM, a patented system of drug
Slide 20: MDI Medical Respiratory division
MDI Medical Respiratory division For personal use only MDI offers a range of devices that can be used to help patients manage and take control of their asthma and COPD. • Space Chamber PlusTM anti-static range • Space Chamber PlusTM aerosol spacer • Space ChamberTM re-usable • Compact Spacer Chamber
Slide 21: MDI Medical Respiratory division
MDI Medical Respiratory division For personal use only Recently approved by the FDA for sale in the USA. Recently approved for full reimbursement in the UK. New distribution partners in the USA (AmerisourceBergen) and first sales. Growing business internationally. MDI now has marketing approvals for
Slide 22: Respiratory division Future
Respiratory division Future For personal use only MDI is investing heavily in developing new and innovative products • Anti static spacers • Anti static mask – (1st of its kind) • Electronic peak flow • Smart phone asthma & COPD applications • Collapsible spacer • Additional patentable devices and t
Slide 23: MDI Corporate Overview
MDI Corporate Overview For personal use only MDI has three business divisions. Pharmaceutical Medical devices Veterinary MDI has been profitable every year since listing on the ASX in 2003 and used those profits for registration and additional clinical studies and: • has generated a positive c
Slide 24: MDI Investor Dashboard
MDI Investor Dashboard (ASX: MVP) For personal use only Historical Stock Chart (3yr) Current stock Price 6.390 ▲0.050 (0.79%) 26 May, 4:00pm Day High 6.470 Day Low 6.250 Open 6.340 Prev. Close 6.370 Volume 80,600 52 Wk. High 6.850 (3 May 2016) 52 Wk. Low 2.100 (25 Aug 2015) Mkt. Cap 368.63 (Mil)
Slide 25: MDI Corporate Overview
MDI Corporate Overview David Williams Dr Harry Oxer Leon Hoare Max Johnston Allan McCallum Phillip Powell For personal use only Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Chairman Director Director Director Director Director The Managing A Medical Consultant
Slide 26: MDI Global strategy
MDI Global strategy New and revised For personal use only materials and process (lowest cost producer and significant IP) New Business Partners Product innovation (worlds best delivery devices and significant IP) Clinical trials (Commercial clinical studies to support marketing and Regulatory produc
Slide 27: Contact details
Contact details For personal use only HEAD OFFICE 4 Caribbean Drive Scoresby, Victoria, Australia, 3179 Tel: +61 3 9547 1888 Fax: +61 3 9547 0262 Web: www.medicaldev.com
Slide 28: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other
Medical Developments International — Non-Deal Roadshow (May 2016) on 6ix